Skip to main content

Table 1 Pharmacokinetics

From: Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study

  Group 1 (n= 25)
ICU, 7,500 IU
Group 2 (n= 29)
ICU, 5,000 IU
Group 3 (n= 29)
Normal ward, 5,000 IU
P overall
AUC-anti-Xa0-12hours (U/l*hour) 2.51 (1.15 to 4.61) 1.27 (1.15 to 4.4) 2.58 (1.45 to 4.87) <0.001*
AUC-anti-Xa12_00 (U/l*hour) 1.37 (0.58 to 13) 1.47 (0.65 to 6.3) 0.89 (0.35 to 3.88) 0.003**
C max-anti-Xa (U/l) 0.29 (0.10 to 0.52) 0.14 (0.1 to 0.43) 0.33 (0.14 to 0.65) <0.001***
t max-anti-Xa (hours) 3 (3 to 12) 4.5 (1 to 12) 3 (3 to 6) 0.017§
  1. Cmax' peak anti-Xa level; t max' time of anti-Xa peak. Medians and range. *Group 1 versus 2, P = 0.001; Group 1 versus 3, P = 0.51. **Group 1 versus 2, P = 0.96; Group 1 versus 3, P = 0.045; Group 2 versus 3, P = 0.13. ***Group 1 versus 2, P = 0.001; Group 1 versus 3, P = 0.29. §Group 1 versus 3, P = 0.09; Group 1 versus 2, P = 0.8; Group 2 versus 3, P = 0.018.